Overview

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carci

Status:
NOT_YET_RECRUITING

Trial end date:
2029-12-30

Target enrollment:

Participant gender:

Summary

This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. The primary endpoint is PFS as assessed by the investigator based on RECIST v1.1 criteria.

Phase:

PHASE2

Details

Lead Sponsor:

Anhui Provincial Hospital

Collaborators:

First Affiliated Hospital of Guangxi Medical University
Henan Provincial People's Hospital
Qilu Hospital of Shandong University
Shaanxi Provincial Cancer Hospital
The Second Affiliated Hospital of Harbin Medical University
Xi'an International Medical Center Hospital

Treatments:

Bevacizumab